Systematic review identifies key prognostic factors for TMD pain and function but emphasizes low-certainty evidence and need for more rigorous research.
Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.